Literature DB >> 30363831

Clinical Features of Patients with Concomitant Parkinson's Disease and Progressive Supranuclear Palsy Pathology.

Heather B Rigby1, Brittany N Dugger2, Joseph G Hentz3, Charles H Adler1, Thomas G Beach2, Holly A Shill4,5, Erika Driver-Dunckley1, Marwan N Sabbagh4,5, Lucia I Sue2, John N Caviness1.   

Abstract

The pathologic changes of Parkinson's disease (PD) and Progressive Supranuclear Palsy (PSP) have been reported to coexist, but whether PSP pathology modifies the clinical course of those individuals is unknown. The aim of this study was to determine whether clinical features of pathologically confirmed PD subjects with concomitant PSP pathology differ from those with PD alone. Subjects enrolled in the Arizona Study of Aging and Neurodegenerative Disorders had annual movement and cognitive evaluations from enrollment until death/autopsy. All cases between 1997 and 2014 with a final clinicopathological diagnosis of PD with or without PSP at autopsy were analyzed. Overall, 12 of the 125 cases with pathologically confirmed PD had coexisting PSP pathology (9.6%). Those with PD-PSP had more-prominent postural instability, body bradykinesia, difficulty arising from a chair, and falls; asymmetric onset was less common in this group. Downgaze palsy and square wave jerks were infrequent in both groups. Gender, age at death, disease duration, rate of dementia, and presence of rest tremor did not differ between groups. Only 58% of subjects in the PD-PSP group were correctly given a final diagnosis in life of PD, compared to 91% of those with PD alone. The combination of PD and PSP pathology yields a heterogeneous clinical syndrome that often resembles PD, but may be more symmetric at onset and have more-prominent postural instability and falls. Our observations suggest that coexisting PSP pathology may be an important factor contributing to the clinical heterogeneity in PD and a potential confounder in diagnosis.

Entities:  

Keywords:  Parkinson's disease; brain bank; neuropathology; progressive supranuclear palsy

Year:  2014        PMID: 30363831      PMCID: PMC6183005          DOI: 10.1002/mdc3.12104

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN: 2330-1619


  40 in total

Review 1.  The identification of Parkinson's disease subtypes using cluster analysis: a systematic review.

Authors:  Stephanie M van Rooden; Willem J Heiser; Joost N Kok; Dagmar Verbaan; Jacobus J van Hilten; Johan Marinus
Journal:  Mov Disord       Date:  2010-06-15       Impact factor: 10.338

2.  PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA.

Authors:  J C STEELE; J C RICHARDSON; J OLSZEWSKI
Journal:  Arch Neurol       Date:  1964-04

3.  Tremor in progressive supranuclear palsy.

Authors:  E F Masucci; J F Kurtzke
Journal:  Acta Neurol Scand       Date:  1989-10       Impact factor: 3.209

Review 4.  Progressive supranuclear palsy: a current review.

Authors:  Michael Lubarsky; Jorge L Juncos
Journal:  Neurologist       Date:  2008-03       Impact factor: 1.398

Review 5.  The neuropathologic diagnosis of secondary parkinsonian syndromes.

Authors:  K A Jellinger
Journal:  Adv Neurol       Date:  1996

6.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

7.  Lewy bodies in progressive supranuclear palsy represent an independent disease process.

Authors:  Hirotake Uchikado; Anthony DelleDonne; Zeshan Ahmed; Dennis W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  2006-04       Impact factor: 3.685

8.  Lewy bodies are not increased in progressive supranuclear palsy compared with normal controls.

Authors:  Y Tsuboi; J E Ahlskog; H Apaydin; J E Parisi; D W Dickson
Journal:  Neurology       Date:  2001-11-13       Impact factor: 9.910

9.  Diffuse Lewy body disease presenting with a supranuclear gaze palsy.

Authors:  J M Fearnley; T Revesz; D J Brooks; R S Frackowiak; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-02       Impact factor: 10.154

10.  LRRK2 phosphorylates novel tau epitopes and promotes tauopathy.

Authors:  Rachel M Bailey; Jason P Covy; Heather L Melrose; Linda Rousseau; Ruth Watkinson; Joshua Knight; Sarah Miles; Matthew J Farrer; Dennis W Dickson; Benoit I Giasson; Jada Lewis
Journal:  Acta Neuropathol       Date:  2013-10-11       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.